SDPA Fall | Live Blog | Product Theater Sponsored by Lilly, USA
Product Theater | “An Expert Review of Clinical Data”
Sponsored by: Lilly, USA
Michael Heffernan, MD
Dr. Michael Heffernan, MD presented an expert review of clinical data on psoriasis during the SDPA’s 14th Annual Fall Dermatology Conference. He highlighted that psoriasis is the most common autoimmune disease in the United States with plaque psoriasis being the most common type. Current treatment modalities include topical treatments with corticosteroids and coal tar, topical and systemic retinoids, phototherapy and immune modifying systemic agents.
Dr. Heffernan explained Taltz (ixekizumab) is an immune modifying systemic agent that is an antagonist of IL-17A. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses, and is involved in the pathophysiology of psoriasis.
Dr. Heffernan highlighted clinical studies that showed improvement of psoriasis PASI scores, as well as sPGA scores with the use of Taltz. At week 12, 9 out of 10 patients had achieved PASI 75 and 8 out of 10 patients achieved sPGA 0 or 1. Interestingly, examination of age, gender, race, body weight and previous treatment with a biologic did not identify differences in treatment response to Taltz among these subgroups.
Taltz is administered as a subcutaneous injection. Recommended dosing is 160mg at week 0 followed by 80 mg biweekly (starting at week 2) for 12 weeks, and then 80 mg monthly.
Dr. Heffernan discussed the most common side effects of Taltz include injection site reactions, upper respiratory tract infections, nausea and tinea infections.
Dr. Heffernan finished by noting that Taltz is the only approved treatment for moderate to severe plaque psoriasis that includes PASI 100 results in the prescribing information, and patients treated with Taltz also found a significant decrease in itching at week 12.
Byline: Sarah Patton, PA-C, MSHS
Posted: November 3, 2016